Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Disease
1.2.3. Regional Scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Disease outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing prevalence of target diseases
3.2.1.2. Advancements in drug delivery and development
3.2.1.3. Rising awareness about early diagnosis and treatment of ocular disorders
3.2.2. Market Restraint Analysis
3.2.2.1. High cost of anti-VEGF therapeutics
3.2.2.2. Potential side effects and safety concerns
3.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Product Movement Analysis
4.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Eylea
4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.6. Lucentis
4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.7. Beovu
4.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.8. Vabysmo
4.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.9. Others
4.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 5. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Disease Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Disease Movement Analysis
5.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Macular Edema
5.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.6. Diabetic Retinopathy
5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.7. Retinal Vein Occlusion
5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.8. Age-related Macular Degeneration
5.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.9. Myopic Choroidal Neovascularization
5.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 6. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Argentina
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Recent Developments & Impact Analysis by Key Market Participants
7.3. Company Market Share Analysis, 2024
7.4. Company overview
7.4.1. Regeneron Pharmaceuticals, Inc.
7.4.1.1. Company Overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Bayer AG
7.4.2.1. Company Overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. Novartis AG
7.4.3.1. Company Overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. F. Hoffmann-La Roche Ltd.
7.4.4.1. Company Overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Biogen
7.4.5.1. Company Overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Pfizer, Inc.
7.4.6.1. Company Overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Coherus BioSciences, Inc.
7.4.7.1. Company Overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Amgen, Inc.
7.4.8.1. Company Overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Bausch Health Companies, Inc.
7.4.9.1. Company Overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Viatris, Inc.
7.4.10.1. Company Overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 4 Global anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 5 North America anti-vascular endothelial growth factor therapeutics, by region, 2018 - 2030 (USD Billion)
Table 6 North America anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 7 North America anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 8 U.S. anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 9 U.S. anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 10 Canada anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 11 Canada anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 12 Mexico anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 13 Mexico anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 14 Europe anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
Table 15 Europe anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 16 Europe anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 17 UK anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 18 UK anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 19 Germany anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 20 Germany anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
Table 21 France anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 22 France anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
Table 23 Italy anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 24 Italy anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 25 Spain anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 26 Spain anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 27 Denmark anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 28 Denmark anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
Table 29 Norway anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 30 Norway anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 31 Sweden anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 32 Sweden anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 33 Asia Pacific anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
Table 34 Asia Pacific anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 35 Asia Pacific anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 36 Japan anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 37 Japan anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 38 China anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 39 China anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
Table 40 India anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 41 India anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 42 Australia anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 43 Australia anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 44 South Korea anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 45 South Korea anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 46 Thailand anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 47 Thailand anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 48 Latin America anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
Table 49 Latin America anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 50 Latin America anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 51 Brazil anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 52 Brazil anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 53 Argentina anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 54 Argentina anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 55 Middle East & Africa anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
Table 56 Middle East & Africa anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 57 Middle East & Africa anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 58 South Africa anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 59 South Africa anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 60 Saudi Arabia anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 61 Saudi Arabia anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 62 UAE anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 63 UAE anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
Table 64 Kuwait anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
Table 65 Kuwait anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
List of Figures
Fig. 1 Anti-vascular endothelial growth factor therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Product and disease segment snapshot
Fig. 10 Competitive landscape snapshot
Fig. 11 Parent market value, 2024 (USD Billion)
Fig. 12 Market dynamics
Fig. 13 Prevalence of diabetic retinopathy in the U.S. in 2021
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Anti-vascular endothelial growth factor therapeutics market: Product outlook and key takeaways
Fig. 17 Anti-vascular endothelial growth factor therapeutics market: Product movement analysis
Fig. 18 Eylea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Lucentis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Beovu market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Vabysmo market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Anti-vascular endothelial growth factor therapeutics market: Disease outlook and key takeaways
Fig. 24 Anti-vascular endothelial growth factor therapeutics market: Disease movement analysis
Fig. 25 Macular edema market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Diabetic retinopathy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Retinal vein occlusion market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Age-related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Myopic choroidal neovascularization market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Anti-vascular endothelial growth factor therapeutics market revenue, by region, 2024 & 2030 USD Million
Fig. 31 Regional marketplace: Key takeaways
Fig. 32 Regional marketplace: Key takeaways
Fig. 33 North America anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Key country dynamics
Fig. 35 U.S. anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Prevalence of Diabetic Retinopathy (DR) in 2021, in U.S., in Million
Fig. 37 Key country dynamics
Fig. 38 Canada anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Key country dynamics
Fig. 40 Mexico anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Europe anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 UK anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Key country dynamics
Fig. 45 Germany anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Key country dynamics
Fig. 47 France anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 Spain anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Key country dynamics
Fig. 51 Italy anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Key country dynamics
Fig. 53 Denmark anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Key country dynamics
Fig. 55 Sweden anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Key country dynamics
Fig. 57 Norway anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Rest of Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Key country dynamics
Fig. 61 Japan anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Key country dynamics
Fig. 63 China anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Key country dynamics
Fig. 65 India anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Key country dynamics
Fig. 67 Australia anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Key country dynamics
Fig. 69 Thailand anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 South Korea anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Rest of Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Latin America anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 Key country dynamics
Fig. 75 Brazil anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Key country dynamics
Fig. 77 Argentina anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Rest of Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 MEA anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Key country dynamics
Fig. 81 South Africa anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 82 Key country dynamics
Fig. 83 Saudi Arabia anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 UAE anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Key country dynamic
Fig. 87 Kuwait anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Rest of MEA anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 Company/competition categorization
Fig. 90 Company market share analysis, 2024
Fig. 91 Strategy mapping
